Russia’s personalized mRNA cancer vaccine Enteromix shows 100% success in early trials

The mRNA-based vaccine, developed by Russian scientists, shrank tumours by up to 80% and showed no severe side effects in initial trials. (Image: @SputnikInt/X)

Russian scientists have unveiled a potential game-changer in cancer care: the Enteromix vaccine, designed to shrink tumours, train the immune system to fight cancer, and avoid the harsh side effects of chemotherapy and radiation.

The Federal Medical and Biological Agency (FMBA) announced that early clinical trials of Enteromix—an mRNA-based cancer vaccine—have shown 100% efficacy and safety.

As reported by Russian agency TASS, the announced made by FMBA head Veronika Skvortsova at the Eastern Economic Forum, signals what could be a major shift in how aggressive cancers are treated.

Also Read: Harvard-trained doctor says these 3 foods can help reduce risk of fatty liver and boost detox

According to Skvortsova, the vaccine has gone through years of research, including three years of mandatory preclinical testing. Results so far suggest the vaccine is not only safe, even after multiple doses, but also highly effective. In some cases, tumours reportedly shrank or slowed their growth by 60–80%, depending on cancer type.

Enteromix will be tailored to each patient, customised to their unique RNA profile. The first rollout is expected for colorectal cancer, with further versions in development for glioblastoma (a type of brain cancer) and certain forms of melanoma (skin cancer).

🚨🇷🇺💉Russian scientists unveil mRNA cancer vaccine ready for use

The Russian Enteromix cancer vaccine is now ready for clinical use, the Federal Medical and Biological Agency (FMBA) has announced.

FMBD head Veronica Skvortsova said the mRNA-based vaccine had successfully… pic.twitter.com/Q91FTK4obk

Story continues below Advertisement

Remove Ad

— Sputnik (@SputnikInt) September 6, 2025

Enteromix was developed using cutting-edge biotechnology, and works in two revolutionary ways. First, it acts as an oncolytic vaccine, built from a blend of four harmless viruses that directly attack cancer cells while supercharging the body's immune defences

Second, it uses personalised mRNA technology—similar to the COVID-19 vaccine platform—tailored to each patient's tumour genetic profile. This brand-new approach empowers the immune system to identify and destroy malignant cells with precision

Also Read: New study finds why acid-reducing vegan diet may help you lose weight faster

In initial trials involving 48 volunteers, scientists reported consistent tumour shrinkage, halted disease progression, and, crucially, no severe side effects.

Researchers also highlighted improved survival rates, underscoring the vaccine’s potential as a safer and more effective alternative to conventional cancer therapies.

However, experts caution that ground-breaking results in early trials are still preliminary. Expanded phase trials, independent validation, and a full regulatory review are essential before Enteromix can enter mainstream clinical use